On August 25, clear aligner leader ANGELALIGN (06699) released its 2025 interim results report, demonstrating robust growth across multiple core metrics while announcing strategic increases in long-term investments across several key areas. During the reporting period, the company's total clear aligner case volume surged 47.7% year-over-year to approximately 225,800 cases, with international market cases growing 103.5% year-over-year to about 117,200 cases, surpassing the 108,600 cases in the Chinese market and showcasing significant achievements in its global expansion strategy.
Driven by rapid case volume growth, combined with continuous optimization of medical design and intelligent manufacturing systems, the company achieved revenues of $161 million in the first half, up 33.1% year-over-year; gross profit reached $101 million; and adjusted net profit totaled $19.5 million, with overall operational quality continuing to improve.
ANGELALIGN leverages its highly efficient and synergistic medical design and digital production platform to continuously advance product innovation and overseas market expansion, demonstrating core competitiveness and long-term growth resilience in the orthodontic field. While achieving impressive results, ANGELALIGN announced plans to further increase investments in sales and marketing, clinical support and customer service, establish and operate international medical design centers and manufacturing facilities, enhance legal capabilities to advance intellectual property strategies and compliance development, and further upgrade data security infrastructure.
The development of R&D-focused intellectual property strategies and global compliance systems has been established as a core priority for the company. As global operations continue to expand, ANGELALIGN is systematically enhancing its legal capabilities from a strategic level, including expanding legal team size and increasing corresponding resource allocation, aiming to build a comprehensive system covering intellectual property creation, protection, and management throughout the entire chain, providing solid compliance support and risk barriers for the company's international operations while enabling stable advancement of global market expansion and innovative business ventures.
Intellectual property serves as both institutional guarantee and core competitiveness for ANGELALIGN's R&D innovation. The company actively deploys comprehensive patent portfolios across major global markets, covering aligner design, material technology, intelligent manufacturing, and diagnostic software. In the first half of 2025, the company not only launched multiple innovative products including the A10 expansion solution, AngelActivator HG headgear-style muscle activator, Angel locking guides, and Angel curved surface guides, but also deeply integrated intelligent initial consultation communication and follow-up monitoring into the treatment process, with all these innovations supported by robust patent systems.
ANGELALIGN places high importance on patent layout during the R&D process, promoting integrated innovation between clinical practice and digital technology, ensuring that each new generation of products and technical solutions can form effective patent barriers. The core of intellectual property management lies not only in protecting proprietary innovations but also in comprehensively complying with regulatory requirements across different global regions. Therefore, ANGELALIGN considers "compliance" as another important pillar of its intellectual property strategy, implementing strict intellectual property compliance reviews throughout the entire product lifecycle to ensure business expansion complies with local laws, regulations, and industry standards, minimizing intellectual property risks in global operations to the greatest extent.
Beyond focused investments in intellectual property, ANGELALIGN continues to increase investments in global supply chain and data security. To meet growing demand in international markets, the company is accelerating the construction of an environmentally friendly, highly scalable world-class intelligent manufacturing system and plans to establish or expand production and medical design centers in multiple regions. Currently, medical design centers in Brazil and Southeast Asia are successfully operating and providing support to the North American market, demonstrating significant efficiency in global resource coordination.
In data security and privacy protection, ANGELALIGN has invested substantial resources to comprehensively upgrade IT infrastructure and operational processes, strictly implementing data protection regulations in all operating regions (such as GDPR, CCPA, etc.), establishing a full lifecycle security management system from data collection and storage to processing. This investment is not only necessary for compliance but also serves as the foundation for earning trust from global users, doctors, and partners.
Looking ahead, ANGELALIGN, with its exceptional product innovation capabilities, efficient global supply chain system, and comprehensive intellectual property layout, has steadily entered a new stage of high-quality growth. The strong resilience and strategic determination demonstrated by the company in its internationalization process not only further consolidates its leading position in the global clear aligner field but also sets an exemplary model for the industry's coordinated development of innovation and compliance.
Following the results announcement, ANGELALIGN's stock price surged strongly, with gains reaching over 9% at one point, fully demonstrating market recognition of its 2025 interim performance and firm confidence in the company's globalization strategy and sustainable growth capabilities.
The global clear aligner market represents a long runway with substantial opportunities. Looking forward, as international market share continues to increase and various strategic investments gradually materialize, ANGELALIGN is expected to further expand its growth ceiling and enter a new trajectory of accelerated value enhancement.